Santos da Silva Jorge 4

What Happened
Santos da Silva Jorge, Chief Executive Officer of MoonLake Immunotherapeutics (MLTX), sold a total of 102,225 shares in two open‑market transactions for gross proceeds of about $2,046,205. On 2026-07-09 he disposed of 33,936 shares at a weighted average price of $20.01 ($679,059 total). On 2026-07-10 he disposed of 68,289 shares at a weighted average price of $20.02 ($1,367,146 total). These were sales (not purchases) and therefore represent distributions of stock rather than an additional investment in the company.

Key Details

• Transaction dates and reported prices:
  • 2026-07-09: 33,936 shares at $20.01 (weighted avg) — $679,059
  • 2026-07-10: 68,289 shares at $20.02 (weighted avg) — $1,367,146
• Total shares sold: 102,225; total gross proceeds ≈ $2,046,205.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes:
  • F1: Sales were executed pursuant to a Rule 10b5-1 trading plan adopted March 31, 2026.
  • F2/F3: Reported prices are weighted averages; individual trades ranged $20.00–$20.03 and $20.00–$20.10. Detailed per‑trade pricing can be provided to the SEC staff on request.
• Filing: Form 4 filed on 2026-07-13 (covers trades on July 9–10) — filing date appears to be within the typical two-business-day reporting window.

Context
A Rule 10b5-1 plan allows insiders to transact at pre-set times and is commonly used to avoid questions about trading on nonpublic information; it does not by itself indicate the insider’s current view of the company. Sales reduce insider stock holdings and generate cash for the insider; they are routine and not as informative as purchases when interpreting insider sentiment.